Embed Notice

HTML Code

<blockquote style="position: relative; padding-left: 55px;"><section><a href="https://zirk.us/users/ChrisMayLA6/statuses/112588618005678401">Emeritus Prof Christopher May (chrismayla6@zirk.us)'s status on Monday, 10-Jun-2024 07:50:00 JST</a><a href="https://zirk.us/@ChrisMayLA6" title="chrismayla6@zirk.us"><img src="https://gnusocial.jp/avatar/89211-48-20230118063718.webp" width="48" height="48" alt="Emeritus Prof Christopher May" style="position: absolute; left: 0; top: 0;">Emeritus Prof Christopher May</a></section><article><p>This isn't said enough:</p><p>High prices for medicine are due to the way that Big Pharma uses the intellectual property system to maintain profits....</p><p>Big pharma is one of the most profitable sectors in the world economy, but they often profit from commercialising research originally done in the non-profit sector(s).</p><p>The IP system doesn't have to be used this way, but IP reform looks too technical for politicians... but it isn't! It just needs political will!</p><p><a href="https://zirk.us/tags/intellectualproperty" rel="tag">#intellectualproperty</a> <a href="https://zirk.us/tags/health" rel="tag">#health</a></p></article><footer><a rel="bookmark" href="https://gnusocial.jp/conversation/3217288#notice-6353949">In conversation</a><time datetime="2024-06-10T07:50:00+09:00" title="Monday, 10-Jun-2024 07:50:00 JST">about 5 months ago</time> <span>from <span><a href="https://zirk.us/@ChrisMayLA6/112588618005678401" rel="external" title="Sent from zirk.us via ActivityPub">zirk.us</a></span></span><a href="https://zirk.us/@ChrisMayLA6/112588618005678401">permalink</a><h4>Attachments</h4><ol><li><label><a rel="external" href="https://gnusocial.jp/attachment/2761127">letter (edited):With the heavy encouragement of pharmaceutical companies, the blame for such shortfalls often falls on the National Institute for Health and Care Excellence (Nice), the public body that advises the NHS on whether medicines represent value for money.But high medicine prices, including that of Enhertu (average course of treatment: £117,857), are not some natural or necessarily occurring thing. While pharmaceutical companies are famously opaque when it comes to the real cost of producing drugs, it has been repeatedly shown that the NHS has been overcharged for similar cancer treatments. Most obviously, Trastuzumab, which is a key component of Enhertu, was previously sold in the UK at a price 10 times its actual cost of production.The non-availability of key drugs is the result of business decisions made by corporations whose primary interest is in keeping prices high to maximise profit. When people’s lives are at stake, this is inexcusable. Even more so when you consider that the monoclonal antibody technology on which Enhertu is partly based was developed with huge amounts of public funding from the UK’s Medical Research Council.In cases where medicines are priced out of reach of the NHS, the government should be prepared to override patents – supporting the manufacture of medicines domestically. Where the public has contributed to drug development, the case for strict conditions on pricing is even stronger.Tim Bierley
Global Justice Now</a></label><br><a href="https://cdn.masto.host/zirkus/media_attachments/files/112/588/613/329/593/416/original/6357f1c552b621ed.png" rel="external">https://cdn.masto.host/zirkus/media_attachments/files/112/588/613/329/593/416/original/6357f1c552b621ed.png</a></li></ol></footer></blockquote>

Corresponding Notice

Embed this notice
Emeritus Prof Christopher May (chrismayla6@zirk.us)'s status on Monday, 10-Jun-2024 07:50:00 JST Emeritus Prof Christopher May
This isn't said enough:
High prices for medicine are due to the way that Big Pharma uses the intellectual property system to maintain profits....
Big pharma is one of the most profitable sectors in the world economy, but they often profit from commercialising research originally done in the non-profit sector(s).
The IP system doesn't have to be used this way, but IP reform looks too technical for politicians... but it isn't! It just needs political will!
#intellectualproperty #health
In conversationabout 5 months ago from zirk.uspermalink
Attachments
1. letter (edited): With the heavy encouragement of pharmaceutical companies, the blame for such shortfalls often falls on the National Institute for Health and Care Excellence (Nice), the public body that advises the NHS on whether medicines represent value for money. But high medicine prices, including that of Enhertu (average course of treatment: £117,857), are not some natural or necessarily occurring thing. While pharmaceutical companies are famously opaque when it comes to the real cost of producing drugs, it has been repeatedly shown that the NHS has been overcharged for similar cancer treatments. Most obviously, Trastuzumab, which is a key component of Enhertu, was previously sold in the UK at a price 10 times its actual cost of production. The non-availability of key drugs is the result of business decisions made by corporations whose primary interest is in keeping prices high to maximise profit. When people’s lives are at stake, this is inexcusable. Even more so when you consider that the monoclonal antibody technology on which Enhertu is partly based was developed with huge amounts of public funding from the UK’s Medical Research Council. In cases where medicines are priced out of reach of the NHS, the government should be prepared to override patents – supporting the manufacture of medicines domestically. Where the public has contributed to drug development, the case for strict conditions on pricing is even stronger. Tim Bierley Global Justice Now
  https://cdn.masto.host/zirkus/media_attachments/files/112/588/613/329/593/416/original/6357f1c552b621ed.png

Public

Embed Notice

HTML Code

Corresponding Notice